G Lacoste

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

Élisabeth Quoix, Rodryg Ramlau, Virginie Westeel et al. · The Lancet Oncology · 2011 · 265 citations

Medicine, Immunology, Oncology +15

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

Élisabeth Quoix, H. Léna, György Losonczy et al. · The Lancet Oncology · 2015 · 207 citations

Medicine, Immunology, Oncology +13

Intralesional Adenovirus-mediated Interleukin-2 Gene Transfer for Advanced Solid Cancers and Melanoma

Reinhard Dummer, Christoph Rochlitz, Thierry Velu et al. · Molecular Therapy · 2008 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17

Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial

Christine Rotonda, Amélie Anota, Mariette Mercier et al. · PLoS ONE · 2015 · 16 citations · Full text

Medicine, Health Sciences, Oncology +16

Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)

Rodryg Ramlau, V. Westeel, Zsolt Pápai et al. · Journal of Clinical Oncology · 2008 · 14 citations

Medicine, Immunology, Oncology +16